| 1 |
Guideline Use of rituximab for the treatment of rheumatoid arthritis: the Latin American context. free! 2008
Soriano ER, Galarza-Maldonado C, Cardiel MH, Pons-Estel BA, Massardo L, Caballero-Uribe CV, Achurra-Castillo AF, Barile-Fabris LA, Chávez-Corrales J, Díaz-Coto JF, Esteva-Spinetti MH, Guibert-Toledano M, Palazuelos FI, Keiserman MW, Lomonte AV, Mota LM, Pineda Villaseñor C, Alarcón GS, Anonymous00427. · Sección Reumatología, Servicio de Clínica Médica, Hospital Italiano de Buenos Aires y Fundación Dr Pedro M. Catoggio para el Progreso de la Reumatología, Buenos Aires, Argentina. · Rheumatology (Oxford). · Pubmed #18463144 links to free full text
This publication has no abstract.
|
| 2 |
Article [Vaccination against yellow fever among patients on immunosuppressors with diagnoses of rheumatic diseases] free! 2009
Mota LM, Oliveira AC, Lima RA, Santos-Neto LL, Tauil PL. · Serviço de Reumatologia, Hospital Universitário de Brasília, Universidade de Brasília, Brasília, DF. · Rev Soc Bras Med Trop. · Pubmed #19287931 links to free full text
Abstract: Yellow fever is endemic in some countries. The anti-yellow fever vaccine is the only effective means of protection but is contraindicated for immunocompromised patients. The aim of this paper was to report on a case series of rheumatological patients who were using immunosuppressors and were vaccinated against this disease. This was a retrospective study by means of a questionnaire applied to these patients, who were vaccinated 60 days before the investigation. Seventy patients of mean age 46 years were evaluated. Most of them were female (90%). There were cases of rheumatoid arthritis (54), systemic lupus erythematosus (11), spondyloarthropathy (5) and systemic sclerosis (2). The therapeutic schemes included methotrexate (42), corticosteroids (22), sulfasalazine (26), leflunomide (18), cyclophosphamide (3) and immunobiological agents (9). Sixteen patients (22.5%) reported some minor adverse effect. Among the eight patients using immunobiological agents, only one presented a mild adverse effect. Among these patients using immunosuppressors, adverse reactions were no more frequent than among immunocompetent individuals. This is the first study on this topic.
|
|
|